The United States has experienced an unprecedented spike in drug shortages during the first quarter of 2024.
A staggering 323 medications were reported in short supply, eclipsing the previous record of 320 shortages set in 2014, as per the American Society of Health-System Pharmacists (ASHP) and the University of Utah Drug Information Service. This monitoring began in 2001 based on reports from health professionals and patient confirmations with pharmaceutical companies.
The shortages span essential and critical care medications, including treatments for childbirth, cancer, and Attention Deficit Hyperactivity Disorder (ADHD). However, the data does not specify the number of patients currently affected.
Historically, from 2016 to 2020, an average drug shortage affected over half a million individuals, predominantly among seniors aged 65 to 85, according to a report by the Department of Health and Human Services to Congress in May last year.
Critical Shortages in Diabetes and Weight Management Treatments
Notably, there is a current shortage of the popular diabetes and weight management injections, Semaglutide, known commercially as Wegovy and Ozempic, as confirmed by the Food and Drug Administration (FDA).
The FDA has recognized a broad array of medications that are now scarce.
“Every category of drugs can experience shortages, particularly generic sterile injectables like those used in cancer chemotherapy and emergency situations in hospitals,” stated ASHP CEO Paul Abramowitz in a recent blog post.
He further highlighted that the ongoing lack of ADHD treatments presents a significant hurdle for both patients and healthcare providers.
Government Agencies Investigate the Causes of Shortages
The Federal Trade Commission and the Department of Health and Human Services launched an inquiry in February to determine if drug wholesalers and purchasers for healthcare facilities might be contributing to these shortages. This investigation aims to ascertain if these entities have reduced generic drug prices excessively, thereby disincentivizing manufacturers from continuing production and deterring new competitors.
